CL2E-SN38 (TFA)

CAT:

804-HY-139909A-01

Size:

1 mg

Price:

Ask

For price, please contact [email protected]

UNSPSC Description: CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor[1].
Target Antigen: Drug-Linker Conjugates for ADC
Type: ADC Related
Related Pathways: Antibody-drug Conjugate/ADC Related
Applications: Cancer-programmed cell death
Field of Research: Cancer
Assay Protocol: https://www.medchemexpress.com/cl2e-sn38-tfa.html
Solubility: DMSO : 100 mg/mL (ultrasonic)
Smiles: O=C1N(C2)C(C(C2=C(C3=C4)CC)=NC3=CC=C4OC(N(C)CCN(C)C(OCC(C=C5)=CC=C5NC([C@H](CCCCN)NC([C@@H](NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N6)C=C6CNC(C(CC7)CCC7CN(C8=O)C(C=C8)=O)=O)=O)=O)CC9=CC=CC=C9)=O)=O)=O)=O)=CC([C@](O)%10CC)=C1COC%10=O.O=C(O)C(F)(F)F
Molecular Weight: 1855.95
References & Citations: [1]Lianqi Liu, et al. Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates. Drug Deliv. 2021 Dec;28(1):2603-2617.
Shipping Conditions: Room Temperature
Clinical Information: No Development Reported